Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1

Basic & Clinical Pharmacology & Toxicology
Abeer A I Sharaf El-Din, Omaima M Abd Allah

Abstract

Amiodarone (AD) is one of the most frequently prescribed anti-arrhythmic agents worldwide, but its effectiveness is limited due to the development of pulmonary toxicity. Several lines of evidence have suggested that AT1 receptor antagonists can attenuate pulmonary fibrosis in different animal models. This study was performed to evaluate the effect of olmesartan medoxomil (OM) on lung injury induced in rats by AD which was assessed biochemically (hydroxyproline content, MDA level and SOD activity), histologically (Ashcroft criteria and Masson's trichrome stain) and immunohistochemically (TGF-β1 expression in lung tissue). The expression levels of TGF-β1 and type I collagen mRNA were also determined by quantitative real-time polymerase chain reaction. Forty-eight adult male rats were randomized into six equal groups: control group, OM control groups, AD group received 40 mg/kg/day, p.o. for 4 weeks to induce pulmonary injury in rats and OM-treated groups received 0.6 and 6 mg/kg/day, p.o. concomitantly with AD for the same period. The results indicated that OM significantly decreased collagen deposition and hydroxyproline content, ameliorated pathological score and decreased the elevation in type I collagen and TGF-ß1 mRNA expres...Continue Reading

References

May 1, 1978·Analytical Biochemistry·M Mihara, M Uchiyama
Apr 1, 1988·Journal of Clinical Pathology·T AshcroftV Timbrell
Jun 1, 1994·Canadian Journal of Physiology and Pharmacology·R G LeederT E Massey
Dec 22, 1995·The Journal of Biological Chemistry·V J Thannickal, B L Fanburg
Oct 16, 1995·European Journal of Pharmacology·M MizunoH Koike
Sep 1, 1996·Proceedings of the Society for Experimental Biology and Medicine·M J Reasor, S Kacew
Oct 23, 1997·Cell Biochemistry and Function·S M RibeiroM L Kluppel
Aug 10, 2000·Environmental Health Perspectives·J A Lasky, A R Brody
Oct 5, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H YoshijiH Fukui
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jun 6, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Makoto MizunoHiroyuki Koike
Apr 23, 2003·Journal of the American Society of Nephrology : JASN·Jean-Jacques BoffaChristos Chatziantoniou
May 16, 2003·Pharmacology & Toxicology·Bruce D UhalGerasimos Filippatos
Aug 2, 2003·British Journal of Pharmacology·Durairaj PunithavathiMary Babu
Jul 28, 2004·Cardiovascular Research·Stephan Rosenkranz
Aug 11, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Li YaoAkira Nishiyama
Aug 28, 2004·Clinics in Chest Medicine·Philippe CamusPascal Foucher
May 17, 2005·American Journal of Respiratory and Critical Care Medicine·Vuokko L KinnulaTim D Oury
Oct 18, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·Anne SturrockJohn R Hoidal
Dec 6, 2005·Molecular and Cellular Biochemistry·Haşim BoyaciCengiz Erçin
Dec 7, 2005·Respiration; International Review of Thoracic Diseases·Hong Wei YaoYuan Lu
Jul 4, 2006·Physiological Reviews·Martin PaulReinhold Kreutz
Feb 24, 2007·Toxicology and Applied Pharmacology·Adrian C NicolescuThomas E Massey
May 24, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Akira HiroseSaburo Onishi
Oct 27, 2007·Antioxidants & Redox Signaling·Katri KoliVuokko L Kinnula
Nov 15, 2007·Antioxidants & Redox Signaling·Brian J Day
Mar 25, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Sohachi FujimotoNaoki Kashihara
May 8, 2008·British Journal of Clinical Pharmacology·Desak Ketut ErnawatiJeffery David Hughes
Jun 18, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Spyros A PapirisEffrosyni D Manali
Jul 16, 2010·Cardiovascular Therapeutics·Paul J LijnenRobert H Fagard
Sep 15, 2010·Heart·Lieselot van Erven, Martin J Schalij
Jul 2, 2011·Journal of the American Society of Nephrology : JASN·Christiane Rüster, Gunter Wolf
Dec 14, 2011·The International Journal of Biochemistry & Cell Biology·Bruce D UhalMaria Molina-Molina
Jun 15, 2012·Cardiovascular Diabetology·Yao-Chen ChuangKwang-Ming Fang
May 28, 2013·Chemico-biological Interactions·Fiona C RothThomas E Massey
Jun 26, 2013·Respiratory Investigation·Junichi TanakaIchiei Narita
Jun 25, 2013·European Journal of Pharmacology·Chang-He NiuJun-Hua Xiao
Nov 1, 2011·International Journal of Stem Cells·Somaya Saad ZagloolHala Gabr Metwally

❮ Previous
Next ❯

Citations

Aug 25, 2017·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·E M El-MohandesY F Hassan
May 12, 2021·Molecular and Cellular Biochemistry·Ghadha Ibrahim Fouad, Mohamed R Mousa
May 10, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jie WengChan Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.